Avenue Therapeutics, Inc.
ATXI
$0.39
-$0.09-18.29%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.22% | -15.96% | -15.90% | 6.78% | 11.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -58.42% | -54.84% | -27.56% | -19.77% | -22.39% |
| Operating Income | 70.87% | 66.73% | 40.66% | 19.77% | 22.39% |
| Income Before Tax | 74.80% | 60.29% | -4.31% | -27.23% | -11.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 74.80% | 60.29% | -4.31% | -27.23% | -11.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -13.64% | -30.77% | -29.63% | -24.07% | -60.36% |
| Net Income | 75.03% | 60.46% | -4.62% | -27.61% | -12.29% |
| EBIT | 70.87% | 66.73% | 40.66% | 19.77% | 22.39% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 94.27% | 88.60% | 52.08% | 95.94% | 87.47% |
| Normalized Basic EPS | 92.12% | 84.12% | -14.29% | 85.29% | 90.30% |
| EPS Diluted | 94.27% | 88.60% | 52.08% | 95.94% | 87.47% |
| Normalized Diluted EPS | 92.12% | 84.12% | -14.29% | 85.29% | 90.30% |
| Average Basic Shares Outstanding | 141.96% | 215.65% | 366.90% | 620.65% | 816.63% |
| Average Diluted Shares Outstanding | 141.96% | 215.65% | 366.90% | 620.65% | 816.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |